QuidelOrtho in the news

QuidelOrtho's stock dropped following mixed Q4 results and 2026 guidance, with lower free cash flow estimates despite exceeding some Q4 metrics.

QuidelOrtho Corp shares are significantly undervalued according to GF Value, yet the company's unprofitability and negative cash flow present a potential value trap.

QuidelOrtho's podcast discussed rapid diagnostics, antibiotic stewardship, and cardiovascular assessment innovations from the 2026 ADLM Conference, aiming to improve clinical decision-making and patient outcomes.

QuidelOrtho is expected to grow due to its product portfolio, mixed Q1 2026 results, and cost-saving initiatives, despite risks from respiratory business dependence.

QuidelOrtho's stock declined sharply after slashing its full-year revenue and earnings guidance, overshadowing a strong second-quarter earnings beat.

QuidelOrtho's stock rating was lowered by Zacks Research, despite strong Q2 earnings that surpassed analyst expectations, with institutional investors actively trading shares.

QuidelOrtho revised its 2026 revenue forecast downward due to reduced COVID testing demand and other market challenges, impacting its investment outlook.

QuidelOrtho reported mixed Q2 2026 results with ex-China revenue growth, but a significant decline in China, leading to lowered full-year guidance and a focus on improving cash flow and reducing debt.

Invesco Ltd. disclosed a 5.1% beneficial ownership stake in QuidelOrtho Corp. through its investment advisers.

QuidelOrtho reported Q2 results with significant guidance cuts for the full year, driven by a soft respiratory market and challenges in China, leading to investor concerns.

Neuberger Berman Group LLC reduced its stake in QuidelOrtho Corp due to the diagnostic testing company's significant financial and operational challenges.

QuidelOrtho's stock partially rebounded, rising nearly 12% after a post-Q2 earnings decline.

McIntyre Partnerships, after a strong Q2, highlights QuidelOrtho's strategy to sell its POC division for $1.5 billion to deleverage and reweight its stock towards peers, forecasting significant growth potential.

QuidelOrtho reported Q2 2026 revenue of $631 million, a 3% increase, driven by Labs and Point of Care, but updated full-year guidance due to China market headwinds.

QuidelOrtho is exploring the sale of a testing unit, attracting interest from private equity firms in the healthcare industry.

QuidelOrtho appointed Micah Young as its new Chief Financial Officer, effective July 6, 2026, bringing over two decades of medical technology finance leadership.

QuidelOrtho acquired LEX Diagnostics and its LEX VELO System, an ultra-fast PCR platform for rapid influenza and COVID-19 testing, to boost its point-of-care molecular diagnostics growth.